Open in interactive viewer → charts, metric popovers & call review

Constellation Software: 19% Growth, 2% Organic, and a Cash-Flow Head Fake

The serial acquirer's Q3 was strong at the top line, but healthcare shrinkage and a Topicus revaluation charge are the real story behind the numbers.
CSU.TO · Earnings Call · 2026-11-09

The headline is acquisition math

Constellation Software reported $3.5 billion of revenue, up 19%, and the first number management put beside it was 2% organic growth. That is the whole Constellation machine in one line: the top line comes from capital deployment, not from a suddenly faster-growth software portfolio. Mark Miller immediately narrowed the lens to recurring revenue, where organic growth was 4%, and argued that the right comparison is maintenance and recurring revenue rather than total organic growth, because licenses fell 17% and professional services fell 5% and both are lumpy and immaterial. “our maintenance and recurring revenue organic growth was 4% in the quarter” — Mark Miller, President and COO · 2026-11-09 he said. Fair enough. But the call was really about two things that made the headline less clean: a shrinking U.S. health care pocket and a cash-flow line that looked worse than the business.

The health care drag is small in dollars, large in narrative

The U.S. health care unit is now the sore thumb. The group was down about 10% in the quarter versus 1% last quarter. Two recently acquired businesses were already shrinking when Constellation bought them, and excluding them the health care group would have been down about 3%. Excluding the whole U.S. health care unit, recurring organic growth would have been about 5%, which is close to the 5% to 7% range Constellation says it has seen since 2016, with 2020 as the exception. Jamal Baksh pushed back on treating the unit as one problem: “the U.S. health care unit is made up of probably like 50 different small businesses, and each of them have their own pros and cons” — Jamal Baksh, CFO or Finance Executive · 2026-11-09. Mark added that Altera is large and disproportionate inside that group. This is not a new theme—Altera has been discussed for quarters—but it has become the main reason Constellation's organic number needs a footnote. On the prior call, Jamal described Altera as a “slow shrinker for the next year or so or a couple of years” — Jamal Baksh, Chief Financial Officer · 2026-08-12. The current call says the investment thesis and IRR expectations are still intact. That may be true, but it also means the reported organic number will keep carrying a business that is intentionally shrinking.

The cash-flow optical illusion, and the Topicus tell

The other awkward line was free cash flow available to shareholders: $443 million, down 16%. Management spent several minutes explaining why that is not a deterioration. Constellation has an obligation to the minority partners in Topicus, and it revalues that obligation every quarter against Topicus' recurring revenue and the Polish shares Topicus holds in Sygnity and Asseco. The charge was $117 million this quarter versus $16 million a year ago; about $77 million of it was simply the Asseco share and Sygnity share prices rising. Jamal was blunt that it is not a cash payment: “Joday will get their proportion of the Sygnity and Asseco shares. So it's actually not a cash obligation.” — Jamal Baksh, CFO or Finance Executive · 2026-11-09 Hold that line flat and free cash flow was up about 3%. Cash from operations was $717 million, up 5%. This is an important distinction, but it also exposes a structural feature: the headline free cash flow metric is now tied to Topicus' success and to Polish public equities. When Topicus does well, the obligation rises and the metric gets noisier. That is not a reason to ignore the number, but it is a reason not to read the 16% decline as a cash leak.

AI is still an experiment, now with a Chief AI Officer

AI has been on every Constellation call for a year, and this one did not mark a monetization inflection. Miller described more than 1,600 businesses running experiments across products, customer support and software development, with best practice sharing as the real advantage.

I would describe us as experimenting hard, running quickly and still early. The spend is not currently material to our results, and I'm not going to give you a forecast.

Mark Miller, President and COO · 2026-11-09
The new organizational wrinkle is Daan's appointment as Chief AI Officer. Mark framed it as a classic head-office role: “It's a classic head office role where you're really not in control of anything, but you share information as much as you can to help people do what they do better.” — Mark Miller, President and COO · 2026-11-09 That is the best practice sharing model applied to AI. It is also not a central R&D bet. Verticalization is mostly through, with more than half of revenue in verticalized buckets, but Mark was careful to say this is not business integration—it is putting similar businesses in the same orbit. The analyst question that mattered was whether AI is disintermediating vertical software. Mark's answer was “Really not to any large degree.” — Mark Miller, President and COO · 2026-11-09 He also said he sees no broad client behavioral shift. Prior calls had the same shape: in August he said development productivity was improving but “we still haven't seen a real pickup in organic growth from it” — Mark Miller, President · 2026-08-12. So AI remains an option, not a current revenue driver.

M&A: more muscle, same competition

The growth engine is still acquisitions. Bernie Anzarouth said activity has been strong for three quarters and is still ongoing, and he rejected the idea that software owners are rushing for the exits: “I don't know that there's a massive trend for everyone throwing in the towel in a software business. I think they're just selling as they feel like selling.” — Bernard Anzarouth, Chief Strategy Officer or Head of M&A · 2026-11-09 Public software prices have bounced since the early-year fear, but private valuations have not really come down because there is still capital and competition. That is the healthy amount of competition Constellation has described for years. Mark added that Constellation has built more muscle for larger, more complicated transactions, which matters because the company's historical edge was small tuck-ins. The most conspicuous omission was PEM investments—the minority-stake strategy that dominated the May call and the prior Q&A. This call did not revisit it. That does not mean the strategy is gone, but it does suggest management wants the narrative back on wholly owned VMS acquisitions and away from public-market minority stakes. As Bernie put it in May, “There's a real disconnect between the SaaSpocalypse publicly traded stuff and private markets.” — Bernard Anzarouth, CFO · 2026-05-13 The current call says that disconnect has not produced cheaper private assets.

What actually changed

Not much, and that is the point. Constellation is still a capital-allocation compounding machine, not an AI growth story. The 19% revenue growth is real, but it is bought. The 2% organic growth is modest, and the 4% recurring organic growth is a better measure but still below the historical range once health care is included. The U.S. health care unit is the visible soft spot, and management is managing it as a portfolio of small businesses rather than a single turnaround. The free cash flow decline is mostly an accounting and minority-obligation effect, not a cash burn. The vertical reorganization is largely done. AI is being tested everywhere, but no one is putting AI revenue into the model. The stock's next move will depend less on the AI narrative than on whether the health care drag stays contained, whether Topicus' mark-to-market obligation keeps distorting the FCF line, and whether Constellation can keep finding larger acquisitions at IRR-clearing prices. On this call, management defended all three without changing the story.